Osimertinib Mesylate Powder: Your Key Pharmaceutical Intermediate
Discover the essential details of this advanced EGFR inhibitor for your pharmaceutical needs.
Get a Quote & SampleProduct Core Value
Osimertinib Mesylate Powder
Osimertinib Mesylate Powder is a critical pharmaceutical intermediate, recognized as a third-generation, orally available, irreversible, mutant-selective epidermal growth factor receptor (EGFR) inhibitor. Its targeted mechanism of action is pivotal in treating specific forms of advanced non-small cell lung cancer (NSCLC), particularly those with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, and the T790M resistance mutation.
- Leveraging Osimertinib Mesylate powder for sale, pharmaceutical companies can secure a vital component for advanced cancer therapies.
- The ability to buy Osimertinib Mesylate API is crucial for R&D and manufacturing of targeted oncology drugs.
- Understanding the properties of Osimertinib Mesylate CAS 1421373-66-1 is key for precise formulation and efficacy.
- Efficient pharmaceutical intermediate sourcing strategies ensure consistent supply for critical treatments.
Key Advantages of Osimertinib Mesylate
Targeted Efficacy
This EGFR inhibitor specifically targets mutant forms of EGFR, potentially leading to a reduced toxicity profile compared to non-selective inhibitors, which is a significant advantage when sourcing this pharmaceutical intermediate.
Mechanism of Action
By covalently binding to and inhibiting various mutant EGFR forms, it effectively prevents EGFR-mediated signaling, crucial for halting tumor growth, making the purchase of Osimertinib Mesylate API a strategic decision.
Oral Administration
The oral availability of Osimertinib Mesylate simplifies patient compliance and administration, a key consideration for companies involved in oncology drug development raw materials.
Key Applications
Non-Small Cell Lung Cancer (NSCLC) Treatment
As a targeted therapy, Osimertinib Mesylate is vital for patients with specific EGFR mutations in NSCLC, supporting the critical need for reliable pharmaceutical intermediate sourcing.
Adjuvant Therapy
Its use in adjuvant treatment after tumor resection highlights its role in improving patient outcomes, emphasizing the importance of accessing quality Osimertinib Mesylate powder for sale.
First-Line and Subsequent Treatments
The compound serves in both first-line treatments and for patients with resistance mutations, underscoring its broad utility in oncology drug development.
Targeted Oncology Formulations
It is a key component in creating advanced targeted oncology formulations, making it a sought-after fine chemical intermediate.